: In Response to Drs. Mavroidis and LindReferences
- Wang JZ, Mayr NA, Yuh WT. Behind EUD. Acta Oncol 2008; 47: 971–2
- Lind BK, Mavroidis P, Hyodynmaa S, Kappas C. Optimization of the dose level for a given treatment plan to maximize the complication-free tumor cure. Acta Oncol 1999; 38: 787–98
- Mavroidis P, Lind BK, Brahme A. Biologically effective uniform dose (D) for specification, report and comparison of dose response relations and treatment plans. Phys Med Biol 2001; 46: 2607–30
- Wigg DR. Plausible parameter values of normal tissues and tumors that may be used for predictive models and bioeffect planning. Applied Radiobiology and Bioeffect Planning. Medical Physics Publishing, Madison, WisconsinUSA 2001; 234–276
- Levegrun S, Jackson A, Zelefsky MJ, Skwarchuk MW, Venkatraman ES, Schlegel W, et al. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: Pitfalls in deducing radiobiologic parameters for tumors from clinical data. Int J Radiat Oncol Biol Phys 2001; 51: 1064–80
- Wang JZ, Guerrero M, Li XA. How low is the α/β ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 2003; 55: 194–203
- Niemierko A. Reporting and analyzing dose distributions: A concept of equivalent uniform dose. Med Phys 1997; 24: 103–10
- Wyatt RM, Beddoe AH, Dale RG. The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol 2003; 48: 139–55
- Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095–101
- Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 6–13
- Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 2001; 50: 1021–31
- King CR, Mayo CS. Is the prostrate alpha/beta ratio of 1.5 from Brenner & Hall a modeling artifact. Int J Radiat Oncol Biol Phys 2000; 47: 536–9
- Wang JZ, Li XA, Yu CX, DiBiase SJ. The low α/β ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol Biol Phys 2003; 57: 1101–8
- Wang JZ, Stewart RD, Carlson DJ, Jennings K, Li XA, Guerrero M. Reply to ‘Comments on ‘Comparison of in vitro and in vivo α/β ratios for prostate cancer’ ’ [letter]. Phys Med Biol 2005; 50: L5–L8